Malignant Ovarian Endometrioid Tumor
4 clinical trials · Condition
◉ Watch Malignant Ovarian Endometrioid Tumor
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04034927) | National Cancer Institute (NCI) | 2019-12-04 |
| Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT02569957) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-10-02 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707) | Mayo Clinic | 2014-02-24 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy (NCT00899093) | Gynecologic Oncology Group | 2007-09-01 |
Track Malignant Ovarian Endometrioid Tumor automatically
Every clearance here is in the API, with alerts when new ones post.